Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

Castration Resistant ◽

Endothelin A Receptor ◽

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration‐Resistant Prostate Cancer

The Oncologist ◽

10.1634/theoncologist.2015-0502 ◽

2016 ◽

Vol 21 (5) ◽

pp. 535 ◽

Cited By ~ 26

Author(s):

Neeraj Agarwal ◽

Jean‐Pascal Machiels ◽

Cristina Suárez ◽

Nancy Lewis ◽

Michaela Higgins ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Receptor Antagonist ◽

Phase I Study ◽

Prolactin Receptor ◽

Metastatic Breast ◽

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer

The Prostate ◽

10.1002/pros.21342 ◽

2011 ◽

Vol 71 (12) ◽

pp. 1264-1275 ◽

Cited By ~ 7

Author(s):

Donald L. Trump ◽

Heather Payne ◽

Kurt Miller ◽

Johann S. de Bono ◽

Joe Stephenson ◽

...

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Castration Resistant ◽

Endothelin A Receptor ◽

Preliminary Study ◽

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer

Expert Opinion on Investigational Drugs ◽

10.1517/13543784.17.8.1237 ◽

2008 ◽

Vol 17 (8) ◽

pp. 1237-1245 ◽

Cited By ~ 27

Author(s):

Ruth Warren ◽

Glenn Liu

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Castration Resistant ◽

Endothelin A Receptor ◽

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,

BJU International ◽

10.1111/j.1464-410x.2010.09638.x ◽

2010 ◽

Vol 106 (7) ◽

pp. 966-973 ◽

Cited By ~ 79

Author(s):

Nicholas D. James ◽

Armelle Caty ◽

Heather Payne ◽

Michael Borre ◽

Bernard A. Zonnenberg ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Receptor Antagonist ◽

Double Blind ◽

Safety And Efficacy ◽

Efficacy Analysis ◽

Castration Resistant ◽

Endothelin A Receptor ◽

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer

PLoS ONE ◽

10.1371/journal.pone.0133803 ◽

2015 ◽

Vol 10 (7) ◽

pp. e0133803 ◽

Cited By ~ 4

Author(s):

Ping Qi ◽

Ming Chen ◽

Li-xiu Zhang ◽

Rui-xia Song ◽

Zhen-hua He ◽

...

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Meta Analysis ◽

Indirect Comparison ◽

Castration Resistant ◽

Endothelin A Receptor ◽

A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2014.08.007 ◽

2015 ◽

Vol 13 (2) ◽

pp. 113-123 ◽

Cited By ~ 21

Author(s):

Kevin D. Courtney ◽

Judith B. Manola ◽

Aymen A. Elfiky ◽

Robert Ross ◽

William K. Oh ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase I Study ◽

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-0564 ◽

2018 ◽

Vol 24 (21) ◽

pp. 5225-5232 ◽

Cited By ~ 10

Author(s):

Shilpa Gupta ◽

Luke T. Nordquist ◽

Mark T. Fleming ◽

William R. Berry ◽

Jingsong Zhang ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Phase I ◽

Phase I Study ◽

Castration Resistant ◽

Receptor Inhibitor

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer

PLoS ONE ◽

10.1371/journal.pone.0202709 ◽

2018 ◽

Vol 13 (8) ◽

pp. e0202709

Author(s):

Michael T. Schweizer ◽

Kathleen Haugk ◽

Jožefa S. McKiernan ◽

Roman Gulati ◽

Heather H. Cheng ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase I Study ◽

Abstract B135: First‐in‐man, first‐in‐class phase I study of two schedules of MK‐2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)

10.1158/1535-7163.targ-09-b135 ◽

2009 ◽

Author(s):

Timothy A. Yap ◽

Kyriakos Papadopoulos ◽

Ivy Fearen ◽

Christopher Carpenter ◽

Liliana Delgado ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Akt Inhibitor ◽

A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of Oncology ◽

10.1093/annonc/mdz248.052 ◽

2019 ◽

Vol 30 ◽

pp. v353

Author(s):

B. Tran ◽

H. Kouros-Mehr ◽

A. Fermin ◽

L. Horvath ◽

F. Roncolato ◽

...

Keyword(s):

Prostate Cancer ◽

T Cell ◽

Phase I ◽

Half Life ◽

Phase I Study ◽

Castration Resistant ◽

Bispecific T Cell Engager